Located in Aurora, Colorado and adjacent to the University of Colorado Anschutz Medical Campus, MenoGeniX began operations in 2012 and filed a series of U.S. and international patent applications. Patents have been issued in the U.S., Australia, Canada, China, Europe, Israel, and Japan. MenoGeniX, Inc., a clinical stage biotechnology company, focuses on the development of drugs for menopause and the menopause-like symptoms that occur in breast and prostate cancer patients. MenoGeniX completed a Phase I clinical trial to investigate the safety and effectiveness of MNGX-100 for treating hot flashes in women with naturally occurring and surgically induced menopause. The trial produced positive results, informing the design for a larger Phase Ib/IIa trial that is being funded by a grant from the National Institutes of Health (NIH).